Wedbush Securities downgraded Exact Sciences EXAS from Outperform to Neutral
Wedbush Securities commented, "Shares of EXAS are up 13% and up 53% in the last month and 12 months vs. a flat and 20% move in the S&P over the same period. It's hard for us to justify a higher valuation at this time given the risks around data, clinical adoption, FDA, and execution. Expectations appear to be high, as well and we remind investors that shares have a history of selloffs following data announcements."
Exact Sciences closed at $11.60 on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in